Publications

2019

Gerke T, Beltran H, Wang X, Lee G-, Sboner A, R Karnes J, et al. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(3):584-590.
Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M, et al. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. Eur Urol Oncol. 2019;2(5):475-482.
Vlachostergios PJ, Geyer JT, Miller J, Kosloff R, Beltran H, Tagawa ST. Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis. J Oncol Pract. 2019;15(6):343-345.
Geyer JT. Myeloid Neoplasms with Germline Predisposition. Pathobiology. 2019;86(1):53-61.
Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30 Suppl 8:viii16-viii22.
Hickman R, Leeman-Neill R, Rosenblum M, Anderson R, Goldman J. Co-existent pilocytic astrocytoma with acute B-cell leukemia within the cerebellum. Neuropathology. 2019;39(5):394-397.
Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, et al. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019;116(23):11390-11395.
Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2019;116(2):631-640.
Patel KR, Taylor BL, Khani F, Guzzo TJ, Scherr DS, Ravishankar R, et al. Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer. Urology. 2019;131:150-156.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700